Targeted ablation of the left middle cervical ganglion prevents ventricular arrhythmias and cardiac injury induced by AMI
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany..
Cardiac sympathetic overactivation is a critical driver in the progression of acute myocardial infarction (AMI). The left middle cervical ganglion (LMCG) is an important extracardiac sympathetic ganglion. However, the regulatory effects of LMCG on AMI have not yet been fully documented. In the present study, we detected that the LMCG was innervated by abundant sympathetic components and exerted an excitatory effect on the cardiac sympathetic nervous system in response to stimulation. In canine models of AMI, targeted ablation of LMCG reduced the sympathetic indexes of heart rate variability and serum norepinephrine, resulting in suppressed cardiac sympathetic activity. Moreover, LMCG ablation could improve ventricular electrophysiological stability, evidenced by the prolonged ventricular effective refractory period, elevated action potential duration, increased ventricular fibrillation threshold, and enhanced connexin43 expression, consequently showing antiarrhythmic effects. Additionally, compared with the control group, myocardial infarction size, circulating cardiac troponin I, and myocardial apoptosis were significantly reduced, accompanied by preserved cardiac function in canines subjected to LMCG ablation. Finally, we performed the left stellate ganglion (LSG) ablation and compared its effects with LMCG destruction. The results indicated that LMCG ablation prevented ventricular electrophysiological instability, cardiac sympathetic activation, and AMI-induced ventricular arrhythmias with similar efficiency as LSG denervation. In conclusion, this study demonstrated that LMCG ablation suppressed cardiac sympathetic activity, stabilized ventricular electrophysiological properties and mitigated cardiomyocyte death, resultantly preventing ischemia-induced ventricular arrhythmias, myocardial injury, and cardiac dysfunction. Neuromodulation therapy targeting LMCG represented a promising strategy for the treatment of AMI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:119 |
|---|---|
| Enthalten in: |
Basic research in cardiology - 119(2024), 1 vom: 01. Feb., Seite 57-74 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheng, Meng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myocardial infarction |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00395-023-01026-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36642226X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36642226X | ||
| 003 | DE-627 | ||
| 005 | 20240205232009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00395-023-01026-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1281.xml |
| 035 | |a (DE-627)NLM36642226X | ||
| 035 | |a (NLM)38151579 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheng, Meng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeted ablation of the left middle cervical ganglion prevents ventricular arrhythmias and cardiac injury induced by AMI |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 05.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. | ||
| 520 | |a Cardiac sympathetic overactivation is a critical driver in the progression of acute myocardial infarction (AMI). The left middle cervical ganglion (LMCG) is an important extracardiac sympathetic ganglion. However, the regulatory effects of LMCG on AMI have not yet been fully documented. In the present study, we detected that the LMCG was innervated by abundant sympathetic components and exerted an excitatory effect on the cardiac sympathetic nervous system in response to stimulation. In canine models of AMI, targeted ablation of LMCG reduced the sympathetic indexes of heart rate variability and serum norepinephrine, resulting in suppressed cardiac sympathetic activity. Moreover, LMCG ablation could improve ventricular electrophysiological stability, evidenced by the prolonged ventricular effective refractory period, elevated action potential duration, increased ventricular fibrillation threshold, and enhanced connexin43 expression, consequently showing antiarrhythmic effects. Additionally, compared with the control group, myocardial infarction size, circulating cardiac troponin I, and myocardial apoptosis were significantly reduced, accompanied by preserved cardiac function in canines subjected to LMCG ablation. Finally, we performed the left stellate ganglion (LSG) ablation and compared its effects with LMCG destruction. The results indicated that LMCG ablation prevented ventricular electrophysiological instability, cardiac sympathetic activation, and AMI-induced ventricular arrhythmias with similar efficiency as LSG denervation. In conclusion, this study demonstrated that LMCG ablation suppressed cardiac sympathetic activity, stabilized ventricular electrophysiological properties and mitigated cardiomyocyte death, resultantly preventing ischemia-induced ventricular arrhythmias, myocardial injury, and cardiac dysfunction. Neuromodulation therapy targeting LMCG represented a promising strategy for the treatment of AMI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myocardial infarction | |
| 650 | 4 | |a Left middle cervical ganglion | |
| 650 | 4 | |a Myocardial injury | |
| 650 | 4 | |a Sympathetic nervous system | |
| 650 | 4 | |a Ventricular arrhythmias | |
| 700 | 1 | |a Chen, Siyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Ziyue |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Huanhuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hanyu |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xiaomei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Weina |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xianqing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chen-Ze |e verfasserin |4 aut | |
| 700 | 1 | |a He, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Ke-Qiong |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Zhibing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Basic research in cardiology |d 1973 |g 119(2024), 1 vom: 01. Feb., Seite 57-74 |w (DE-627)NLM000047120 |x 1435-1803 |7 nnns |
| 773 | 1 | 8 | |g volume:119 |g year:2024 |g number:1 |g day:01 |g month:02 |g pages:57-74 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00395-023-01026-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 119 |j 2024 |e 1 |b 01 |c 02 |h 57-74 | ||